Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and ...

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Trump Cuts Tariff Rate to 15% on Japan - The U.S. and Japan struck a major trade deal overnight. Trump confirmed a 15% tariff ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility]( ...